Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial

Jon Lampa; D.C. Nordström; R Van Vollenhoven; Merete Lund Hetland; Espen Haavardsholm; Mikkel Østergaard; Anna Rudin; Marte Schrumpf Heiberg; Michael Nurmohamed; Bjorn Gudbjornsson; Kristina Lend; K Hørsley-Petersen; Tuulikki Sokka-Isler; G. Gröndal; S Krabbe; Joakim Lindqvist; Anna-Karin Hultgård Ekwall; Daniel Erik Glinatsi; Meliha Crnkic Kapetanovic; C.  Gentline; A-B Aga; Heikki Relas; T Lorenzen; Giovanni Cagnotto; Johan Back; O Hendricks; B. Dijkshoorn; K Öberg; Maud-Kristine Aga Ljoså; E Brodin; H. Lindegaard; A Söderbergh; Milad Rizk; Alf Kastbom; P Larsson; L Uhrenholt; S. Just; D. Stevens; T. Laurberg; G Bakland; I Olsen; J. Sexton; T Uhlig

doi:https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/

Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial

Jon Lampa, D.C. Nordström, R Van Vollenhoven, Merete Lund Hetland, Espen Haavardsholm, Mikkel Østergaard, Anna Rudin, Marte Schrumpf Heiberg, Michael Nurmohamed, Bjorn Gudbjornsson, Kristina Lend, K Hørsley-Petersen, Tuulikki Sokka-Isler, G. Gröndal, S Krabbe, Joakim Lindqvist, Anna-Karin Hultgård Ekwall, Daniel Erik Glinatsi, Meliha Crnkic Kapetanovic, C. GentlineA-B Aga, Heikki Relas, T Lorenzen, Giovanni Cagnotto, Johan Back, O Hendricks, B. Dijkshoorn, K Öberg, Maud-Kristine Aga Ljoså, E Brodin, H. Lindegaard, A Söderbergh, Milad Rizk, Alf Kastbom, P Larsson, L Uhrenholt, S. Just, D. Stevens, T. Laurberg, G Bakland, I Olsen, J. Sexton, T Uhlig

Department for Rheumatology and Spine Diseases

Original language	English
Publication date	2023
DOIs	https://doi.org/https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/
Publication status	Published - 2023
Event	ACR Convergence 2023 - San Diego, United States Duration: 10 Nov 2023 → 15 Nov 2023

Conference

Conference	ACR Convergence 2023
Country/Territory	United States
City	San Diego
Period	10/11/2023 → 15/11/2023

Access to Document

https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/

Cite this

Lampa, J., Nordström, D. C., Van Vollenhoven, R., Hetland, M. L., Haavardsholm, E., Østergaard, M., Rudin, A., Schrumpf Heiberg, M., Nurmohamed, M., Gudbjornsson, B., Lend, K., Hørsley-Petersen, K., Sokka-Isler, T., Gröndal, G., Krabbe, S., Lindqvist, J., Hultgård Ekwall, A.-K., Glinatsi, D. E., Kapetanovic, M. C., ... Uhlig, T. (2023). Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial. Artrhitis Rheumatology 75, suppl. 9. Abstract from ACR Convergence 2023, San Diego, United States. https://doi.org/https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/

Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial. / Lampa, Jon; Nordström, D.C.; Van Vollenhoven, R et al.
2023. Artrhitis Rheumatology 75, suppl. 9 Abstract from ACR Convergence 2023, San Diego, United States.

Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

Lampa, J, Nordström, DC, Van Vollenhoven, R, Hetland, ML, Haavardsholm, E, Østergaard, M, Rudin, A, Schrumpf Heiberg, M, Nurmohamed, M, Gudbjornsson, B, Lend, K, Hørsley-Petersen, K, Sokka-Isler, T, Gröndal, G, Krabbe, S, Lindqvist, J, Hultgård Ekwall, A-K, Glinatsi, DE, Kapetanovic, MC, Gentline, C, Aga, A-B, Relas, H, Lorenzen, T, Cagnotto, G, Back, J, Hendricks, O, Dijkshoorn, B, Öberg, K, Ljoså, M-KA, Brodin, E, Lindegaard, H, Söderbergh, A, Rizk, M, Kastbom, A, Larsson, P, Uhrenholt, L, Just, S, Stevens, D, Laurberg, T, Bakland, G, Olsen, I, Sexton, J & Uhlig, T 2023, 'Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial', ACR Convergence 2023, San Diego, United States, 10/11/2023 - 15/11/2023 pp. Artrhitis Rheumatology 75, suppl. 9. https://doi.org/https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/

Lampa J, Nordström DC, Van Vollenhoven R, Hetland ML, Haavardsholm E, Østergaard M et al.. Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial. 2023. Abstract from ACR Convergence 2023, San Diego, United States. doi: https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/

@conference{8fb427a719a746d8b9913fb4fa95a56a,

title = "Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial",

author = "Jon Lampa and D.C. Nordstr{\"o}m and {Van Vollenhoven}, R and Hetland, {Merete Lund} and Espen Haavardsholm and Mikkel {\O}stergaard and Anna Rudin and {Schrumpf Heiberg}, Marte and Michael Nurmohamed and Bjorn Gudbjornsson and Kristina Lend and K H{\o}rsley-Petersen and Tuulikki Sokka-Isler and G. Gr{\"o}ndal and S Krabbe and Joakim Lindqvist and {Hultg{\aa}rd Ekwall}, Anna-Karin and Glinatsi, {Daniel Erik} and Kapetanovic, {Meliha Crnkic} and C. Gentline and A-B Aga and Heikki Relas and T Lorenzen and Giovanni Cagnotto and Johan Back and O Hendricks and B. Dijkshoorn and K {\"O}berg and Ljos{\aa}, {Maud-Kristine Aga} and E Brodin and H. Lindegaard and A S{\"o}derbergh and Milad Rizk and Alf Kastbom and P Larsson and L Uhrenholt and S. Just and D. Stevens and T. Laurberg and G Bakland and I Olsen and J. Sexton and T Uhlig",

note = "COPECARE; ACR Convergence 2023 ; Conference date: 10-11-2023 Through 15-11-2023",

year = "2023",

doi = "https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/",

language = "English",

pages = "Artrhitis Rheumatology 75, suppl. 9",

}

TY - ABST

T1 - Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial

AU - Lampa, Jon

AU - Nordström, D.C.

AU - Van Vollenhoven, R

AU - Hetland, Merete Lund

AU - Haavardsholm, Espen

AU - Østergaard, Mikkel

AU - Rudin, Anna

AU - Schrumpf Heiberg, Marte

AU - Nurmohamed, Michael

AU - Gudbjornsson, Bjorn

AU - Lend, Kristina

AU - Hørsley-Petersen, K

AU - Sokka-Isler, Tuulikki

AU - Gröndal, G.

AU - Krabbe, S

AU - Lindqvist, Joakim

AU - Hultgård Ekwall, Anna-Karin

AU - Glinatsi, Daniel Erik

AU - Kapetanovic, Meliha Crnkic

AU - Gentline, C.

AU - Aga, A-B

AU - Relas, Heikki

AU - Lorenzen, T

AU - Cagnotto, Giovanni

AU - Back, Johan

AU - Hendricks, O

AU - Dijkshoorn, B.

AU - Öberg, K

AU - Ljoså, Maud-Kristine Aga

AU - Brodin, E

AU - Lindegaard, H.

AU - Söderbergh, A

AU - Rizk, Milad

AU - Kastbom, Alf

AU - Larsson, P

AU - Uhrenholt, L

AU - Just, S.

AU - Stevens, D.

AU - Laurberg, T.

AU - Bakland, G

AU - Olsen, I

AU - Sexton, J.

AU - Uhlig, T

N1 - COPECARE

PY - 2023

Y1 - 2023

U2 - https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/

DO - https://acrabstracts.org/abstract/certolizumab-pegol-abatacept-tocilizumab-or-active-conventional-therapy-in-early-rheumatoid-arthritis-48-week-patient-reported-outcomes-of-the-nord-star-trial/

M3 - Conference abstract for conference

SP - Artrhitis Rheumatology 75, suppl. 9

T2 - ACR Convergence 2023

Y2 - 10 November 2023 through 15 November 2023

ER -